You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCimetidine
Accession NumberDB00501  (APRD00568)
TypeSmall Molecule
GroupsApproved
DescriptionA histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant therapy. [PubChem]
Structure
Thumb
Synonyms
1-Cyano-2-methyl-3-(2-(((5-methyl-4-imidazolyl)methyl)thio)ethyl)guanidine
2-Cyano-1-methyl-3-(2-(((5-methylimidazol-4-yl)methyl)thio)ethyl)guanidine
Cimetag
Cimetidin
Cimetidina
Cimétidine
Cimetidinum
N-Cyano-n'-methyl-n''-(2-([(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl)ethyl)guanidine
N''-cyano-N-methyl-n'-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]thio}ethyl)guanidine
Tagamet hb 200
Ulcerfen
External Identifiers
  • SKF 92334
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Cimetidine 200 Tab 200mgTablet200 mgOralPro Doc Limitee1984-12-312009-07-23Canada
Cimetidine Tab 300mgTablet300 mgOralPro Doc Limitee1983-12-312010-07-13Canada
Cimetidine Tab 400mgTablet400 mgOralPro Doc Limitee1984-12-312009-07-23Canada
Cimetidine Tab 600mgTablet600 mgOralPro Doc Limitee1984-12-312012-07-23Canada
Dom-cimetidineTablet600 mgOralDominion Pharmacal2000-06-19Not applicableCanada
Dom-cimetidineTablet300 mgOralDominion Pharmacal2000-06-19Not applicableCanada
Dom-cimetidineTablet800 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-cimetidineTablet400 mgOralDominion Pharmacal2000-06-19Not applicableCanada
Dom-cimetidineTablet200 mgOralDominion PharmacalNot applicableNot applicableCanada
Gen-cimetidine Tablets 200mgTablet200 mgOralGenpharm Ulc1997-05-302009-08-05Canada
Mylan-cimetidineTablet300 mgOralMylan Pharmaceuticals Ulc1997-05-30Not applicableCanada
Mylan-cimetidineTablet400 mgOralMylan Pharmaceuticals Ulc1997-05-30Not applicableCanada
Mylan-cimetidineTablet600 mgOralMylan Pharmaceuticals Ulc1997-05-30Not applicableCanada
Mylan-cimetidineTablet800 mgOralMylan Pharmaceuticals Ulc1997-05-30Not applicableCanada
Novo-cimetineTablet600 mgOralTeva Canada Limited1983-12-31Not applicableCanada
Novo-cimetineTablet800 mgOralTeva Canada Limited1987-12-31Not applicableCanada
Novo-cimetineTablet200 mgOralTeva Canada Limited1983-12-31Not applicableCanada
Novo-cimetineTablet300 mgOralTeva Canada Limited1983-12-31Not applicableCanada
Novo-cimetineTablet400 mgOralTeva Canada Limited1983-12-31Not applicableCanada
Novo-cimetine InjectionSolution150 mgIntramuscular; IntravenousTeva Canada Limited1997-09-022015-04-30Canada
Nu-cimet Tab 200mgTablet200 mgOralNu Pharm Inc1990-12-312012-09-04Canada
Nu-cimet Tab 300mgTablet300 mgOralNu Pharm Inc1990-12-312012-09-04Canada
Nu-cimet Tab 400mgTablet400 mgOralNu Pharm Inc1990-12-312012-09-04Canada
Nu-cimet Tab 600mgTablet600 mgOralNu Pharm Inc1990-12-312012-09-04Canada
Peptol Tab 200mgTablet200 mgOralCarter Horner Corp.1981-12-312004-07-09Canada
Peptol Tab 300mgTablet300 mgOralCarter Horner Corp.1981-12-312004-07-09Canada
Peptol Tab 400mgTablet400 mgOralCarter Horner Corp.1982-12-312004-07-09Canada
Peptol Tab 600mgTablet600 mgOralCarter Horner Corp.1983-12-312004-07-09Canada
Peptol Tab 800mgTablet800 mgOralCarter Horner Corp.1984-12-312004-07-09Canada
PMS-cimetidineTablet600 mgOralPharmascience Inc1998-02-05Not applicableCanada
PMS-cimetidineTablet200 mgOralPharmascience Inc1998-02-05Not applicableCanada
PMS-cimetidineTablet800 mgOralPharmascience Inc1998-02-05Not applicableCanada
PMS-cimetidineTablet300 mgOralPharmascience Inc1998-02-05Not applicableCanada
PMS-cimetidineTablet400 mgOralPharmascience Inc1998-02-05Not applicableCanada
Tagamet 300Tablet300 mgOralGlaxosmithkline Inc1992-12-312002-02-04Canada
Tagamet 400Tablet400 mgOralGlaxosmithkline Inc1993-12-312002-02-04Canada
Tagamet 600Tablet600 mgOralGlaxosmithkline Inc1992-12-312002-02-04Canada
Tagamet Infusion 6mg/mlLiquid6 mgIntravenousSmithkline Beecham Pharma Division Of Smithkline Beecham Inc1992-12-311999-03-24Canada
Tagamet Inj 150mg/mlLiquid150 mgIntramuscular; IntravenousSmithkline Beecham Pharma Division Of Smithkline Beecham Inc1995-12-311998-08-31Canada
Tagamet Liq 300mg/5mlLiquid300 mgOralSmith Kline & French Canada Ltd.1982-12-311997-08-15Canada
Tagamet Liquid 60mg/mlLiquid60 mgOralGlaxosmithkline Inc1993-12-312002-07-31Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Cimetidine Tab 200mgTablet200 mgOralApotex Inc1982-12-31Not applicableCanada
Apo Cimetidine Tab 300mgTablet300 mgOralApotex Inc1982-12-31Not applicableCanada
Apo Cimetidine Tab 400mgTablet400 mgOralApotex Inc1983-12-31Not applicableCanada
Apo Cimetidine Tab 600mgTablet600 mgOralApotex Inc1983-12-31Not applicableCanada
Apo-cimetidine Oral SolutionLiquid300 mgOralApotex Inc2001-01-05Not applicableCanada
Apo-cimetidine Tab 800mgTablet800 mgOralApotex Inc1988-12-31Not applicableCanada
CimetidineTablet, film coated400 mg/1OralPd Rx Pharmaceuticals, Inc.2011-05-04Not applicableUs
CimetidineTablet400 mg/1OralLiberty Pharmaceuticals, Inc.2010-11-24Not applicableUs
CimetidineTablet, film coated200 mg/1OralCarilion Materials Management1994-05-17Not applicableUs
CimetidineTablet400 mg/1OralREMEDYREPACK INC.2010-11-242016-10-13Us
CimetidineTablet, film coated800 mg/1OralA S Medication Solutions2003-12-06Not applicableUs
CimetidineTablet, film coated300 mg/1OralTeva Pharmaceuticals USA Inc2003-11-24Not applicableUs
CimetidineTablet, film coated400 mg/1OralSTAT Rx USA LLC2010-05-26Not applicableUs
CimetidineTablet, film coated300 mg/1OralREMEDYREPACK INC.2014-08-01Not applicableUs
CimetidineTablet, film coated400 mg/1Oralbryant ranch prepack2010-10-01Not applicableUs
CimetidineTablet, film coated300 mg/1OralMylan Pharmaceuticals Inc.1994-05-17Not applicableUs
CimetidineTablet, film coated300 mg/1OralPhysicians Total Care, Inc.1994-06-22Not applicableUs
CimetidineTablet, film coated400 mg/1OralBlenheim Pharmacal, Inc.2014-01-14Not applicableUs
CimetidineTablet, film coated300 mg/1OralCarilion Materials Management2003-11-24Not applicableUs
CimetidineTablet400 mg/1OralREMEDYREPACK INC.2011-07-142016-10-28Us
CimetidineTablet, film coated400 mg/1OralNu Care Pharmaceuticals, Inc.2004-02-02Not applicableUs
CimetidineTablet, film coated400 mg/1OralTeva Pharmaceuticals USA Inc2004-02-02Not applicableUs
CimetidineTablet, film coated300 mg/1Oralbryant ranch prepack2003-11-24Not applicableUs
CimetidineTablet, film coated800 mg/1OralSTAT Rx USA LLC2010-05-26Not applicableUs
CimetidineTablet, film coated400 mg/1OralCarilion Materials Management2004-02-02Not applicableUs
CimetidineTablet, film coated400 mg/1OralPhysicians Total Care, Inc.1994-07-25Not applicableUs
CimetidineTablet, film coated400 mg/1OralMylan Pharmaceuticals Inc.1994-05-17Not applicableUs
CimetidineTablet, film coated300 mg/1OralBlenheim Pharmacal, Inc.2014-01-14Not applicableUs
CimetidineTablet, film coated300 mg/1OralA S Medication Solutions2003-11-24Not applicableUs
CimetidineTablet, film coated400 mg/1OralProficient Rx LP2004-02-02Not applicableUs
CimetidineTablet, film coated800 mg/1OralTeva Pharmaceuticals USA Inc2003-12-06Not applicableUs
CimetidineTablet, film coated300 mg/1OralAv Kare, Inc.2016-01-12Not applicableUs
CimetidineTablet, film coated400 mg/1OralPreferred Pharmaceuticals, Inc.2011-07-06Not applicableUs
CimetidineTablet, film coated400 mg/1OralAidarex Pharmaceuticals LLC2004-02-02Not applicableUs
CimetidineTablet, film coated800 mg/1OralPhysicians Total Care, Inc.1994-05-23Not applicableUs
CimetidineTablet, film coated800 mg/1OralMylan Pharmaceuticals Inc.1994-05-17Not applicableUs
CimetidineTablet, film coated300 mg/1OralSTAT Rx USA LLC1994-05-17Not applicableUs
CimetidineTablet, film coated400 mg/1OralA S Medication Solutions2004-02-02Not applicableUs
CimetidineTablet, film coated800 mg/1Oralbryant ranch prepack2003-12-06Not applicableUs
CimetidineTablet, film coated200 mg/1OralMylan Pharmaceuticals Inc.1994-05-17Not applicableUs
CimetidineTablet, film coated300 mg/1OralREMEDYREPACK INC.2013-05-28Not applicableUs
CimetidineTablet, film coated400 mg/1OralA S Medication Solutions2004-02-02Not applicableUs
CimetidineTablet, film coated400 mg/1OralDispensing Solutions, Inc.2010-05-26Not applicableUs
CimetidineTablet, film coated400 mg/1OralAv Kare, Inc.2013-07-23Not applicableUs
Cimetidine HydrochlorideSolution300 mg/5mLOralMorton Grove Pharmaceuticals, Inc.1997-03-12Not applicableUs
Cimetidine Hydrochloride Oral SolutionSolution300 mg/5mLOralHi Tech Pharmacal Co., Inc.1997-10-28Not applicableUs
Good Sense Heartburn ReliefTablet200 mg/1Oralbryant ranch prepack2002-12-30Not applicableUs
Approved Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Acid ReducerTablet200 mg/1OralKroger Company2015-10-21Not applicableUs
Acid ReducerTablet200 mg/1OralRite Aid Corporation2005-07-08Not applicableUs
Cimetidine Acid ReducerTablet200 mg/1OralWalgreen Company2001-03-27Not applicableUs
Dg Health Heartburn ReliefTablet200 mg/1OralDolgencorp, LLC2010-03-02Not applicableUs
Equaline Acid ReducerTablet200 mg/1OralSupervalu Inc2004-09-15Not applicableUs
Equate CimetidineTablet200 mg/1OralWal Mart Stores Inc2006-09-27Not applicableUs
Gaviscon All-nightTablet100 mgOralGlaxosmithkline Consumer Healthcare Inc.Not applicableNot applicableCanada
Gaviscon PreventTablet100 mgOralGlaxosmithkline Consumer Healthcare Inc.1998-08-172002-07-31Canada
Gaviscon Prevent Extra StrengthTablet200 mgOralGlaxosmithkline Consumer Healthcare Inc.Not applicableNot applicableCanada
Good Neighbor Pharmacy Heartburn ReliefTablet200 mg/1OralAmerisource Bergen2000-01-05Not applicableUs
Good Sense Heartburn ReliefTablet200 mg/1OralL. Perrigo Company2002-12-30Not applicableUs
Harris Teeter Acid ReducerTablet200 mg/1OralHarris Teeter, LLC2015-03-30Not applicableUs
Heartburn ReliefTablet200 mg/1OralMeijer Distribution Inc2000-01-05Not applicableUs
Heartburn ReliefTablet200 mg/1OralFamily Dollar Services Inc2000-09-18Not applicableUs
Heartburn ReliefTablet200 mg/1OralCVS Pharmacy2000-01-14Not applicableUs
Leader Heartburn ReliefTablet200 mg/1OralCardinal Health2000-02-04Not applicableUs
Smart Sense Acid ReducerTablet200 mg/1OralKmart Corporation2000-01-06Not applicableUs
Sunmark Heartburn Relief Acid ReducerTablet200 mg/1OralMc Kesson2003-09-19Not applicableUs
TagametTablet200 mg/1OralMedtech Products Inc.2012-06-01Not applicableUs
Topcare Heartburn ReliefTablet200 mg/1OralTopco Associates LLC2000-02-22Not applicableUs
Up and Up Acid ReducerTablet200 mg/1OralTarget Corporation2010-05-12Not applicableUs
Unapproved/Other Products Not Available
International Brands
NameCompany
CimetagJulphar
Tagamet HB200GlaxoSmithKline
UlcedineNot Available
UlcerfenFinadiet
UlcimetFarmasa
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Cimetidine Hydrochloride
70059-30-2
Thumb
  • InChI Key: QJHCNBWLPSXHBL-UHFFFAOYSA-N
  • Monoisotopic Mass: 288.092392971
  • Average Mass: 288.8
DBSALT000287
Categories
UNII80061L1WGD
CAS number51481-61-9
WeightAverage: 252.339
Monoisotopic: 252.115715232
Chemical FormulaC10H16N6S
InChI KeyAQIXAKUUQRKLND-UHFFFAOYSA-N
InChI
InChI=1S/C10H16N6S/c1-8-9(16-7-15-8)5-17-4-3-13-10(12-2)14-6-11/h7H,3-5H2,1-2H3,(H,15,16)(H2,12,13,14)
IUPAC Name
(Z)-1-cyano-2-methyl-3-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl)guanidine
SMILES
C\N=C(\NCCSCC1=C(C)NC=N1)NC#N
Pharmacology
IndicationFor the treatment and the management of acid-reflux disorders (GERD), peptic ulcer disease, heartburn, and acid indigestion.
Structured Indications
PharmacodynamicsCimetidine is a histamine H2-receptor antagonist. It reduces basal and nocturnal gastric acid secretion and a reduction in gastric volume, acidity, and amount of gastric acid released in response to stimuli including food, caffeine, insulin, betazole, or pentagastrin. It is used to treat gastrointestinal disorders such as gastric or duodenal ulcer, gastroesophageal reflux disease, and pathological hypersecretory conditions. Cimetidine inhibits many of the isoenzymes of the hepatic CYP450 enzyme system. Other actions of Cimetidine include an increase in gastric bacterial flora such as nitrate-reducing organisms.
Mechanism of actionCimetidine binds to an H2-receptor located on the basolateral membrane of the gastric parietal cell, blocking histamine effects. This competitive inhibition results in reduced gastric acid secretion and a reduction in gastric volume and acidity.
TargetKindPharmacological actionActionsOrganismUniProt ID
Histamine H2 receptorProteinyes
antagonist
HumanP25021 details
Related Articles
AbsorptionRapid 60-70%
Volume of distributionNot Available
Protein binding15-20%
Metabolism

Hepatic

Route of eliminationThe principal route of excretion of cimetidine is the urine.
Half life2 hours
ClearanceNot Available
ToxicitySymptoms of overdose include nausea, vomiting, diarrhea, increased saliva production, difficulty breathing, and a fast heartbeat.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Cimetidine Action PathwayDrug actionSMP00232
Cimetidine Metabolism PathwayDrug metabolismSMP00617
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Cimetidine.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Cimetidine.Experimental, Illicit
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may decrease the sedative activities of Cimetidine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Cimetidine.Experimental, Illicit
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Cimetidine.Experimental, Illicit
AcebutololThe serum concentration of Acebutolol can be decreased when it is combined with Cimetidine.Approved
AcenocoumarolCimetidine may increase the anticoagulant activities of Acenocoumarol.Approved
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Cimetidine.Approved
AcetohexamideThe serum concentration of Acetohexamide can be increased when it is combined with Cimetidine.Withdrawn
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Cimetidine.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be decreased when it is combined with Cimetidine.Approved, Vet Approved
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Cimetidine.Approved
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Cimetidine.Approved
AjmalineThe metabolism of Ajmaline can be decreased when combined with Cimetidine.Approved
AlbendazoleThe serum concentration of Cimetidine can be increased when it is combined with Albendazole.Approved, Vet Approved
AldosteroneThe serum concentration of Aldosterone can be decreased when it is combined with Cimetidine.Experimental
AlectinibThe serum concentration of Cimetidine can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Alfentanil can be increased when it is combined with Cimetidine.Approved, Illicit
AlitretinoinThe serum concentration of Alitretinoin can be decreased when it is combined with Cimetidine.Approved, Investigational
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Cimetidine.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Cimetidine.Approved
AlprenololThe metabolism of Alprenolol can be decreased when combined with Cimetidine.Approved, Withdrawn
AmantadineThe serum concentration of Cimetidine can be increased when it is combined with Amantadine.Approved
AmbrisentanThe serum concentration of Ambrisentan can be decreased when it is combined with Cimetidine.Approved, Investigational
Ambroxol acefyllinateThe metabolism of Ambroxol acefyllinate can be decreased when combined with Cimetidine.Experimental
AmineptineThe metabolism of Amineptine can be decreased when combined with Cimetidine.Illicit, Withdrawn
Aminohippuric acidThe serum concentration of Cimetidine can be increased when it is combined with Aminohippuric acid.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Cimetidine.Approved, Withdrawn
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Cimetidine.Approved
AmiodaroneThe serum concentration of Amiodarone can be increased when it is combined with Cimetidine.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Cimetidine.Approved
AmlodipineThe serum concentration of Amlodipine can be increased when it is combined with Cimetidine.Approved
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Cimetidine.Approved
AmoxapineThe metabolism of Amoxapine can be decreased when combined with Cimetidine.Approved
AmoxicillinThe metabolism of Amoxicillin can be decreased when combined with Cimetidine.Approved, Vet Approved
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Cimetidine.Approved, Illicit
AmprenavirThe serum concentration of Cimetidine can be decreased when it is combined with Amprenavir.Approved
AmrinoneThe serum concentration of Amrinone can be increased when it is combined with Cimetidine.Approved
AmsacrineThe serum concentration of Cimetidine can be increased when it is combined with Amsacrine.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Cimetidine.Approved
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Cimetidine.Approved
AprepitantThe metabolism of Aprepitant can be decreased when combined with Cimetidine.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Cimetidine.Approved
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Cimetidine.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Cimetidine.Approved, Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be decreased when it is combined with Cimetidine.Approved, Investigational
ArtemetherThe metabolism of Artemether can be decreased when combined with Cimetidine.Approved
AstemizoleThe serum concentration of Cimetidine can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Cimetidine.Approved, Investigational
AtenololThe serum concentration of Atenolol can be decreased when it is combined with Cimetidine.Approved
AtomoxetineThe metabolism of Atomoxetine can be decreased when combined with Cimetidine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Cimetidine.Approved
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Cimetidine.Approved, Investigational
AzelastineThe serum concentration of Cimetidine can be increased when it is combined with Azelastine.Approved
AzelnidipineThe serum concentration of Azelnidipine can be increased when it is combined with Cimetidine.Approved
AzimilideThe serum concentration of Azimilide can be increased when it is combined with Cimetidine.Investigational
AzithromycinThe serum concentration of Cimetidine can be increased when it is combined with Azithromycin.Approved
BarnidipineThe serum concentration of Barnidipine can be increased when it is combined with Cimetidine.Approved
BenidipineThe serum concentration of Benidipine can be increased when it is combined with Cimetidine.Approved
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Cimetidine.Approved
BenzocaineThe serum concentration of Cimetidine can be increased when it is combined with Benzocaine.Approved
BenzphetamineBenzphetamine may decrease the sedative activities of Cimetidine.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Cimetidine.Approved
Benzylpenicilloyl PolylysineCimetidine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BepridilThe serum concentration of Bepridil can be increased when it is combined with Cimetidine.Approved, Withdrawn
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Cimetidine.Approved
BetamethasoneThe serum concentration of Betamethasone can be decreased when it is combined with Cimetidine.Approved, Vet Approved
BetaxololThe metabolism of Betaxolol can be decreased when combined with Cimetidine.Approved
BiperidenThe serum concentration of Cimetidine can be increased when it is combined with Biperiden.Approved
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Cimetidine.Approved
BoceprevirThe serum concentration of Boceprevir can be decreased when it is combined with Cimetidine.Approved
BortezomibThe metabolism of Bortezomib can be decreased when combined with Cimetidine.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Cimetidine.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Cimetidine.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Cimetidine.Approved
BromazepamThe serum concentration of Bromazepam can be increased when it is combined with Cimetidine.Approved, Illicit
BromocriptineThe serum concentration of Bromocriptine can be decreased when it is combined with Cimetidine.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Cimetidine.Approved
BufuralolThe metabolism of Bufuralol can be decreased when combined with Cimetidine.Experimental, Investigational
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Cimetidine.Approved, Investigational
BuprenorphineThe serum concentration of Cimetidine can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of Cimetidine can be increased when it is combined with Bupropion.Approved
BuspironeThe serum concentration of Cimetidine can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe serum concentration of Cabazitaxel can be decreased when it is combined with Cimetidine.Approved
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Cimetidine.Approved
CaiThe serum concentration of Cai can be increased when it is combined with Cimetidine.Investigational
CamptothecinThe serum concentration of Camptothecin can be decreased when it is combined with Cimetidine.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be decreased when it is combined with Cimetidine.Approved
CandesartanThe serum concentration of Cimetidine can be increased when it is combined with Candesartan.Approved
CapecitabineThe serum concentration of the active metabolites of Capecitabine can be increased when Capecitabine is used in combination with Cimetidine.Approved, Investigational
CaptoprilThe serum concentration of Cimetidine can be increased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Cimetidine.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Cimetidine.Approved
CarfilzomibThe serum concentration of Carfilzomib can be decreased when it is combined with Cimetidine.Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Cimetidine.Approved
CarisoprodolThe metabolism of Carisoprodol can be decreased when combined with Cimetidine.Approved
CarmustineCimetidine may increase the myelosuppressive activities of Carmustine.Approved
CarteololThe metabolism of Carteolol can be decreased when combined with Cimetidine.Approved
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Cimetidine.Approved, Investigational
CaspofunginThe serum concentration of Cimetidine can be increased when it is combined with Caspofungin.Approved
CefditorenThe serum concentration of Cefditoren can be decreased when it is combined with Cimetidine.Approved
CefpodoximeCimetidine can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
CefuroximeCimetidine can cause a decrease in the absorption of Cefuroxime resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CephalexinThe metabolism of Cephalexin can be decreased when combined with Cimetidine.Approved, Vet Approved
CeritinibThe serum concentration of Ceritinib can be decreased when it is combined with Cimetidine.Approved
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Cimetidine.Withdrawn
CevimelineThe metabolism of Cevimeline can be decreased when combined with Cimetidine.Approved
ChloramphenicolThe metabolism of Chloramphenicol can be decreased when combined with Cimetidine.Approved, Vet Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Cimetidine.Approved, Illicit
ChloroquineThe serum concentration of Cimetidine can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Cimetidine.Approved
ChlorphentermineChlorphentermine may decrease the sedative activities of Cimetidine.Illicit, Withdrawn
ChlorpromazineThe serum concentration of Chlorpromazine can be decreased when it is combined with Cimetidine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Chlorpropamide can be increased when it is combined with Cimetidine.Approved
ChlorprothixeneThe serum concentration of Cimetidine can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Cimetidine.Approved
CholesterolThe serum concentration of Cimetidine can be increased when it is combined with Cholesterol.Experimental
Cholic AcidCimetidine may decrease the excretion rate of Cholic Acid which could result in a higher serum level.Approved
CilazaprilThe serum concentration of Cimetidine can be increased when it is combined with Cilazapril.Approved
CilnidipineThe serum concentration of Cilnidipine can be increased when it is combined with Cimetidine.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Cimetidine.Approved
CinnarizineThe serum concentration of Cinnarizine can be increased when it is combined with Cimetidine.Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be decreased when it is combined with Cimetidine.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Cimetidine.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be decreased when it is combined with Cimetidine.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Cimetidine.Approved
ClarithromycinThe serum concentration of Clarithromycin can be decreased when it is combined with Cimetidine.Approved
ClevidipineThe serum concentration of Clevidipine can be increased when it is combined with Cimetidine.Approved
ClobazamThe serum concentration of Clobazam can be decreased when it is combined with Cimetidine.Approved, Illicit
ClofazimineThe serum concentration of Cimetidine can be increased when it is combined with Clofazimine.Approved, Investigational
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Cimetidine.Investigational
ClomifeneThe serum concentration of Clomifene can be decreased when it is combined with Cimetidine.Approved, Investigational
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Cimetidine.Approved, Vet Approved
ClonidineThe serum concentration of Clonidine can be decreased when it is combined with Cimetidine.Approved
ClopidogrelThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Cimetidine resulting in a loss in efficacy.Approved, Nutraceutical
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Cimetidine.Approved, Illicit
ClotrimazoleThe serum concentration of Cimetidine can be decreased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Cimetidine.Approved
CobicistatThe serum concentration of Cimetidine can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be decreased when it is combined with Cimetidine.Approved
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Cimetidine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Cimetidine.Approved
ColforsinThe serum concentration of Cimetidine can be increased when it is combined with Colforsin.Experimental
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Cimetidine.Approved
CrizotinibThe serum concentration of Crizotinib can be decreased when it is combined with Cimetidine.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Cimetidine.Approved
CyclophosphamideThe serum concentration of Cimetidine can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cimetidine can be decreased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CysteamineThe therapeutic efficacy of Cysteamine can be decreased when used in combination with Cimetidine.Approved, Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Cimetidine.Approved
DabrafenibThe serum concentration of Dabrafenib can be decreased when it is combined with Cimetidine.Approved
DaclatasvirThe serum concentration of Cimetidine can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Dactinomycin can be decreased when it is combined with Cimetidine.Approved
DalfampridineThe serum concentration of Dalfampridine can be increased when it is combined with Cimetidine.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be decreased when it is combined with Cimetidine.Approved
DapoxetineThe metabolism of Dapoxetine can be decreased when combined with Cimetidine.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Cimetidine.Approved, Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Cimetidine.Approved, Investigational
DarodipineThe serum concentration of Darodipine can be increased when it is combined with Cimetidine.Experimental
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Cimetidine.Approved
DasatinibCimetidine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be decreased when it is combined with Cimetidine.Approved
DebrisoquinThe serum concentration of Debrisoquin can be decreased when it is combined with Cimetidine.Approved
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Cimetidine.Approved
DesipramineThe metabolism of Desipramine can be decreased when combined with Cimetidine.Approved
DesloratadineThe serum concentration of Cimetidine can be increased when it is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Cimetidine.Approved
DexamethasoneThe serum concentration of Cimetidine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Cimetidine.Approved, Illicit, Withdrawn
DexmethylphenidateCimetidine can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Cimetidine.Approved, Illicit
DextromethorphanThe serum concentration of Cimetidine can be increased when it is combined with Dextromethorphan.Approved
DiazepamThe serum concentration of Diazepam can be decreased when it is combined with Cimetidine.Approved, Illicit, Vet Approved
DiclofenacThe serum concentration of Cimetidine can be increased when it is combined with Diclofenac.Approved, Vet Approved
DicoumarolCimetidine may increase the anticoagulant activities of Dicoumarol.Approved
DiethylpropionDiethylpropion may decrease the sedative activities of Cimetidine.Approved, Illicit
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Cimetidine.Approved
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Cimetidine.Approved
DigoxinThe serum concentration of Cimetidine can be decreased when it is combined with Digoxin.Approved
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Cimetidine.Approved, Illicit
DihydroergotamineThe serum concentration of Cimetidine can be increased when it is combined with Dihydroergotamine.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be decreased when it is combined with Cimetidine.Illicit
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Cimetidine.Approved
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Cimetidine.Approved
DipyridamoleThe serum concentration of Dipyridamole can be decreased when it is combined with Cimetidine.Approved
DocetaxelThe serum concentration of Docetaxel can be decreased when it is combined with Cimetidine.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Cimetidine.Approved
DolasetronThe metabolism of Dolasetron can be decreased when combined with Cimetidine.Approved
DomperidoneThe serum concentration of Domperidone can be decreased when it is combined with Cimetidine.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Cimetidine.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Cimetidine.Approved
DosulepinThe metabolism of Dosulepin can be decreased when combined with Cimetidine.Approved
DotarizineThe serum concentration of Dotarizine can be increased when it is combined with Cimetidine.Investigational
DoxazosinThe serum concentration of Cimetidine can be increased when it is combined with Doxazosin.Approved
DoxepinThe metabolism of Doxepin can be decreased when combined with Cimetidine.Approved
DoxofyllineThe serum concentration of Doxofylline can be increased when it is combined with Cimetidine.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Cimetidine.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Cimetidine.Approved, Investigational
DronabinolThe serum concentration of Cimetidine can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe serum concentration of Cimetidine can be increased when it is combined with Dronedarone.Approved
DuloxetineThe metabolism of Duloxetine can be decreased when combined with Cimetidine.Approved
DyphyllineThe metabolism of Dyphylline can be decreased when combined with Cimetidine.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Cimetidine.Approved
EfonidipineThe serum concentration of Efonidipine can be increased when it is combined with Cimetidine.Approved
ElbasvirThe serum concentration of Cimetidine can be increased when it is combined with Elbasvir.Approved
EletriptanThe serum concentration of Eletriptan can be decreased when it is combined with Cimetidine.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Cimetidine.Approved
EnalaprilThe serum concentration of Cimetidine can be increased when it is combined with Enalapril.Approved, Vet Approved
EncainideThe metabolism of Encainide can be decreased when combined with Cimetidine.Approved, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Cimetidine.Investigational
EnfuvirtideThe metabolism of Enfuvirtide can be decreased when combined with Cimetidine.Approved, Investigational
EnzalutamideThe serum concentration of Cimetidine can be increased when it is combined with Enzalutamide.Approved
EperisoneThe serum concentration of Eperisone can be increased when it is combined with Cimetidine.Approved, Investigational
EpinastineThe serum concentration of Epinastine can be decreased when it is combined with Cimetidine.Approved, Investigational
EpirubicinThe serum concentration of Epirubicin can be increased when it is combined with Cimetidine.Approved
ErgonovineThe serum concentration of Cimetidine can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Cimetidine can be increased when it is combined with Ergotamine.Approved
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Cimetidine.Approved, Investigational
ErythromycinThe serum concentration of Erythromycin can be decreased when it is combined with Cimetidine.Approved, Vet Approved
EscitalopramThe serum concentration of Escitalopram can be increased when it is combined with Cimetidine.Approved, Investigational
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Cimetidine.Investigational
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Cimetidine.Approved, Investigational
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Cimetidine.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Cimetidine can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Estriol can be decreased when it is combined with Cimetidine.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be decreased when it is combined with Cimetidine.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Cimetidine.Approved
Ethyl biscoumacetateCimetidine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Cimetidine.Approved, Illicit
EtoperidoneThe metabolism of Etoperidone can be decreased when combined with Cimetidine.Approved
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Cimetidine.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Cimetidine.Approved, Investigational
EtravirineThe serum concentration of Cimetidine can be increased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Cimetidine.Approved
EzetimibeThe serum concentration of Ezetimibe can be decreased when it is combined with Cimetidine.Approved
FamotidineThe metabolism of Famotidine can be decreased when combined with Cimetidine.Approved
FelodipineThe serum concentration of Felodipine can be increased when it is combined with Cimetidine.Approved, Investigational
FendilineThe serum concentration of Fendiline can be increased when it is combined with Cimetidine.Withdrawn
FentanylThe serum concentration of Cimetidine can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
Ferric CarboxymaltoseCimetidine can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric CitrateCimetidine can cause a decrease in the absorption of Ferric Citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric pyrophosphateCimetidine can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Cimetidine.Approved
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Cimetidine.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be decreased when it is combined with Cimetidine.Approved
FingolimodThe metabolism of Fingolimod can be decreased when combined with Cimetidine.Approved, Investigational
FlecainideThe metabolism of Flecainide can be decreased when combined with Cimetidine.Approved, Withdrawn
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Cimetidine.Approved
FloxuridineThe serum concentration of the active metabolites of Floxuridine can be increased when Floxuridine is used in combination with Cimetidine.Approved
FluconazoleThe serum concentration of Cimetidine can be increased when it is combined with Fluconazole.Approved
FluindioneCimetidine may increase the anticoagulant activities of Fluindione.Investigational
FlunarizineThe serum concentration of Flunarizine can be increased when it is combined with Cimetidine.Approved
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Cimetidine.Approved, Illicit
FluorouracilThe serum concentration of Fluorouracil can be increased when it is combined with Cimetidine.Approved
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Cimetidine.Approved, Vet Approved
FlupentixolThe serum concentration of Cimetidine can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Cimetidine can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Cimetidine can be increased when it is combined with Flurazepam.Approved, Illicit
FlutamideThe metabolism of Flutamide can be decreased when combined with Cimetidine.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be decreased when it is combined with Cimetidine.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Cimetidine.Approved
FluvoxamineThe metabolism of Fluvoxamine can be decreased when combined with Cimetidine.Approved, Investigational
FormoterolThe metabolism of Formoterol can be decreased when combined with Cimetidine.Approved, Investigational
FosamprenavirThe serum concentration of Fosamprenavir can be decreased when it is combined with Cimetidine.Approved
FosphenytoinThe risk or severity of adverse effects can be increased when Cimetidine is combined with Fosphenytoin.Approved
GabapentinThe serum concentration of Gabapentin can be increased when it is combined with Cimetidine.Approved, Investigational
GalantamineThe metabolism of Galantamine can be decreased when combined with Cimetidine.Approved
GallopamilThe serum concentration of Gallopamil can be increased when it is combined with Cimetidine.Investigational
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Cimetidine.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be decreased when it is combined with Cimetidine.Approved
GenisteinThe serum concentration of Cimetidine can be increased when it is combined with Genistein.Investigational
GlibornurideThe serum concentration of Glibornuride can be increased when it is combined with Cimetidine.Withdrawn
GliclazideThe serum concentration of Gliclazide can be increased when it is combined with Cimetidine.Approved
GlimepirideThe serum concentration of Glimepiride can be increased when it is combined with Cimetidine.Approved
GlipizideThe serum concentration of Glipizide can be increased when it is combined with Cimetidine.Approved
GliquidoneThe serum concentration of Gliquidone can be increased when it is combined with Cimetidine.Approved
GlisoxepideThe serum concentration of Glisoxepide can be increased when it is combined with Cimetidine.Approved
GlucosamineThe metabolism of Glucosamine can be decreased when combined with Cimetidine.Approved
GlyburideThe serum concentration of Glyburide can be increased when it is combined with Cimetidine.Approved
GlycerolThe serum concentration of Cimetidine can be increased when it is combined with Glycerol.Experimental
Gramicidin DThe serum concentration of Cimetidine can be increased when it is combined with Gramicidin D.Approved
GranisetronThe metabolism of Granisetron can be decreased when combined with Cimetidine.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be decreased when it is combined with Cimetidine.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Cimetidine.Withdrawn
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Cimetidine.Approved, Investigational
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Cimetidine.Approved
HaloperidolThe serum concentration of Haloperidol can be decreased when it is combined with Cimetidine.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Cimetidine.Approved, Vet Approved
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Cimetidine.Approved
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Cimetidine.Approved, Investigational
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Cimetidine.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Cimetidine.Approved, Vet Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Cimetidine.Approved, Illicit
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may decrease the sedative activities of Cimetidine.Approved
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Cimetidine.Approved
IbuprofenThe serum concentration of Ibuprofen can be decreased when it is combined with Cimetidine.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Cimetidine.Approved
IdelalisibThe serum concentration of Idelalisib can be decreased when it is combined with Cimetidine.Approved
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Cimetidine.Approved
IloperidoneThe metabolism of Iloperidone can be decreased when combined with Cimetidine.Approved
ImatinibThe serum concentration of Imatinib can be decreased when it is combined with Cimetidine.Approved
ImipramineThe metabolism of Imipramine can be decreased when combined with Cimetidine.Approved
IndacaterolThe serum concentration of Indacaterol can be decreased when it is combined with Cimetidine.Approved
IndalpineThe metabolism of Indalpine can be decreased when combined with Cimetidine.Investigational, Withdrawn
IndinavirThe serum concentration of Indinavir can be decreased when it is combined with Cimetidine.Approved
IndomethacinThe serum concentration of Indomethacin can be decreased when it is combined with Cimetidine.Approved, Investigational
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Cimetidine.Approved
IrinotecanThe serum concentration of Irinotecan can be decreased when it is combined with Cimetidine.Approved, Investigational
IronCimetidine can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranCimetidine can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Iron saccharateCimetidine can cause a decrease in the absorption of Iron saccharate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IsavuconazoniumThe serum concentration of Cimetidine can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsradipineThe serum concentration of Isradipine can be increased when it is combined with Cimetidine.Approved
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Cimetidine.Approved, Investigational
IvacaftorThe serum concentration of Cimetidine can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be decreased when it is combined with Cimetidine.Approved, Vet Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Cimetidine.Approved
KetamineThe serum concentration of Cimetidine can be increased when it is combined with Ketamine.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be decreased when it is combined with Cimetidine.Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Cimetidine.Approved
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Cimetidine.Approved, Investigational
LabetalolThe metabolism of Labetalol can be decreased when combined with Cimetidine.Approved
LacidipineThe serum concentration of Lacidipine can be increased when it is combined with Cimetidine.Approved
LamivudineThe serum concentration of Lamivudine can be decreased when it is combined with Cimetidine.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Cimetidine.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be decreased when it is combined with Cimetidine.Approved, Investigational
LapatinibThe serum concentration of Cimetidine can be increased when it is combined with Lapatinib.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Cimetidine.Approved
LenalidomideThe serum concentration of Lenalidomide can be decreased when it is combined with Cimetidine.Approved
LenvatinibThe serum concentration of Lenvatinib can be decreased when it is combined with Cimetidine.Approved
LercanidipineThe serum concentration of Lercanidipine can be increased when it is combined with Cimetidine.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be decreased when it is combined with Cimetidine.Approved, Investigational
LevodopaThe metabolism of Levodopa can be decreased when combined with Cimetidine.Approved
LevofloxacinThe serum concentration of Levofloxacin can be decreased when it is combined with Cimetidine.Approved, Investigational
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Cimetidine.Approved
LevothyroxineThe serum concentration of Cimetidine can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Cimetidine can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Cimetidine.Approved
LiothyronineThe serum concentration of Cimetidine can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Cimetidine can be decreased when it is combined with Liotrix.Approved
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Cimetidine.Approved, Investigational
LisinoprilThe serum concentration of Cimetidine can be increased when it is combined with Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Cimetidine.Approved
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Cimetidine.Approved
LomustineThe metabolism of Lomustine can be decreased when combined with Cimetidine.Approved
LoperamideThe serum concentration of Loperamide can be decreased when it is combined with Cimetidine.Approved
LopinavirThe serum concentration of Cimetidine can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Cimetidine can be increased when it is combined with Loratadine.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Cimetidine.Approved
LosartanThe serum concentration of Losartan can be decreased when it is combined with Cimetidine.Approved
LovastatinThe serum concentration of Cimetidine can be increased when it is combined with Lovastatin.Approved, Investigational
LumacaftorThe serum concentration of Cimetidine can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Cimetidine.Approved, Investigational
MacitentanThe metabolism of Macitentan can be decreased when combined with Cimetidine.Approved
Magnesium SulfateThe serum concentration of Magnesium Sulfate can be increased when it is combined with Cimetidine.Approved, Vet Approved
ManidipineThe serum concentration of Manidipine can be increased when it is combined with Cimetidine.Approved
MannitolThe serum concentration of Mannitol can be decreased when it is combined with Cimetidine.Approved, Investigational
MaprotilineThe serum concentration of Cimetidine can be increased when it is combined with Maprotiline.Approved
MebendazoleThe serum concentration of Mebendazole can be increased when it is combined with Cimetidine.Approved, Vet Approved
MefloquineThe serum concentration of Cimetidine can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Cimetidine can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MelatoninThe metabolism of Melatonin can be decreased when combined with Cimetidine.Approved, Nutraceutical, Vet Approved
MephedroneMephedrone may decrease the sedative activities of Cimetidine.Investigational
MephentermineMephentermine may decrease the sedative activities of Cimetidine.Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Cimetidine.Investigational, Withdrawn
MeprobamateThe serum concentration of Cimetidine can be increased when it is combined with Meprobamate.Approved, Illicit
MequitazineThe metabolism of Mequitazine can be decreased when combined with Cimetidine.Approved
MesalazineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Cimetidine.Approved
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Cimetidine.Approved
MetforminThe serum concentration of Metformin can be increased when it is combined with Cimetidine.Approved
MethadoneThe serum concentration of Cimetidine can be increased when it is combined with Methadone.Approved
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Cimetidine.Approved, Illicit
MethotrexateThe serum concentration of Methotrexate can be decreased when it is combined with Cimetidine.Approved
MethotrimeprazineThe metabolism of Methotrimeprazine can be decreased when combined with Cimetidine.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Cimetidine.Approved, Vet Approved
MethsuximideThe metabolism of Methsuximide can be decreased when combined with Cimetidine.Approved
MethylphenidateCimetidine can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
MethylphenobarbitalThe metabolism of Methylphenobarbital can be decreased when combined with Cimetidine.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be decreased when it is combined with Cimetidine.Approved, Vet Approved
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Cimetidine.Approved, Illicit, Withdrawn
MetoclopramideThe metabolism of Metoclopramide can be decreased when combined with Cimetidine.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Cimetidine.Approved, Investigational
MexiletineThe metabolism of Mexiletine can be decreased when combined with Cimetidine.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Cimetidine.Approved
MibefradilThe serum concentration of Mibefradil can be increased when it is combined with Cimetidine.Withdrawn
MiconazoleThe serum concentration of Cimetidine can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Midazolam can be decreased when it is combined with Cimetidine.Approved, Illicit
MifepristoneThe serum concentration of Cimetidine can be decreased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe metabolism of Milnacipran can be decreased when combined with Cimetidine.Approved
MinaprineThe metabolism of Minaprine can be decreased when combined with Cimetidine.Approved
MirabegronThe serum concentration of Mirabegron can be decreased when it is combined with Cimetidine.Approved
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Cimetidine.Approved
MitomycinThe serum concentration of Cimetidine can be increased when it is combined with Mitomycin.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be decreased when it is combined with Cimetidine.Approved, Investigational
MMDAMMDA may decrease the sedative activities of Cimetidine.Experimental, Illicit
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Cimetidine.Approved
MorphineThe serum concentration of Morphine can be decreased when it is combined with Cimetidine.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Cimetidine.Approved, Investigational
NadololThe serum concentration of Nadolol can be decreased when it is combined with Cimetidine.Approved
NaftopidilThe serum concentration of Naftopidil can be increased when it is combined with Cimetidine.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Cimetidine.Approved
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Cimetidine.Approved, Vet Approved
NaltrexoneThe serum concentration of Cimetidine can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaringeninThe serum concentration of Cimetidine can be increased when it is combined with Naringenin.Experimental
NateglinideThe metabolism of Nateglinide can be decreased when combined with Cimetidine.Approved, Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Cimetidine.Approved, Investigational
NefazodoneThe metabolism of Nefazodone can be decreased when combined with Cimetidine.Approved, Withdrawn
NelfinavirThe serum concentration of Nelfinavir can be decreased when it is combined with Cimetidine.Approved
NeostigmineThe serum concentration of Cimetidine can be increased when it is combined with Neostigmine.Approved, Vet Approved
NetupitantThe metabolism of Netupitant can be decreased when combined with Cimetidine.Approved
NevirapineThe metabolism of Nevirapine can be decreased when combined with Cimetidine.Approved
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Cimetidine.Approved
NicergolineThe metabolism of Nicergoline can be decreased when combined with Cimetidine.Approved
NicotineThe serum concentration of Nicotine can be increased when it is combined with Cimetidine.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Cimetidine.Approved
NiguldipineThe serum concentration of Niguldipine can be increased when it is combined with Cimetidine.Experimental
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Cimetidine.Approved, Investigational
NiludipineThe serum concentration of Niludipine can be increased when it is combined with Cimetidine.Experimental
NilutamideThe metabolism of Nilutamide can be decreased when combined with Cimetidine.Approved
NilvadipineThe serum concentration of Nilvadipine can be increased when it is combined with Cimetidine.Approved
NimesulideThe serum concentration of Nimesulide can be increased when it is combined with Cimetidine.Approved, Withdrawn
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Cimetidine.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Cimetidine.Approved
NisoldipineThe serum concentration of Nisoldipine can be increased when it is combined with Cimetidine.Approved
NitrazepamThe serum concentration of Cimetidine can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Nitrendipine can be increased when it is combined with Cimetidine.Approved
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Cimetidine.Approved, Vet Approved
NizatidineThe serum concentration of Nizatidine can be decreased when it is combined with Cimetidine.Approved
NorethisteroneThe serum concentration of Cimetidine can be decreased when it is combined with Norethisterone.Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Cimetidine.Approved
OlanzapineThe serum concentration of Olanzapine can be decreased when it is combined with Cimetidine.Approved, Investigational
OmbitasvirThe serum concentration of Ombitasvir can be decreased when it is combined with Cimetidine.Approved
OmeprazoleThe serum concentration of Cimetidine can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe metabolism of Ondansetron can be decreased when combined with Cimetidine.Approved
OpipramolThe metabolism of Opipramol can be decreased when combined with Cimetidine.Investigational
OsimertinibThe serum concentration of Osimertinib can be decreased when it is combined with Cimetidine.Approved
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Cimetidine.Approved
OxiconazoleThe metabolism of Oxiconazole can be decreased when combined with Cimetidine.Approved
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Cimetidine.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Cimetidine.Approved, Investigational, Vet Approved
P-NitrophenolThe serum concentration of Cimetidine can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Paclitaxel can be decreased when it is combined with Cimetidine.Approved, Vet Approved
Palmitic AcidThe serum concentration of Cimetidine can be increased when it is combined with Palmitic Acid.Experimental
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Cimetidine.Approved, Investigational
PanobinostatThe serum concentration of Panobinostat can be decreased when it is combined with Cimetidine.Approved, Investigational
PantoprazoleThe serum concentration of Cimetidine can be increased when it is combined with Pantoprazole.Approved
ParoxetineThe metabolism of Paroxetine can be decreased when combined with Cimetidine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Cimetidine.Approved
PentamidineThe metabolism of Pentamidine can be decreased when combined with Cimetidine.Approved
PentobarbitalThe metabolism of Pentobarbital can be decreased when combined with Cimetidine.Approved, Vet Approved
PentoxifyllineThe serum concentration of Pentoxifylline can be increased when it is combined with Cimetidine.Approved, Investigational
PerhexilineThe serum concentration of Perhexiline can be increased when it is combined with Cimetidine.Approved
PerindoprilThe serum concentration of Cimetidine can be increased when it is combined with Perindopril.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Cimetidine.Approved
PethidineThe serum concentration of Pethidine can be increased when it is combined with Cimetidine.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Cimetidine.Withdrawn
PhenforminThe metabolism of Phenformin can be decreased when combined with Cimetidine.Approved, Withdrawn
PhenindioneCimetidine may increase the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe serum concentration of Phenobarbital can be decreased when it is combined with Cimetidine.Approved
PhenprocoumonCimetidine may increase the anticoagulant activities of Phenprocoumon.Approved
PhenterminePhentermine may decrease the sedative activities of Cimetidine.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Cimetidine is combined with Phenytoin.Approved, Vet Approved
PimozideThe serum concentration of Pimozide can be increased when it is combined with Cimetidine.Approved
PinaveriumThe serum concentration of Pinaverium can be increased when it is combined with Cimetidine.Approved
PindololThe metabolism of Pindolol can be decreased when combined with Cimetidine.Approved
PiperazineThe metabolism of Piperazine can be decreased when combined with Cimetidine.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Cimetidine.Approved
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Cimetidine.Approved
Platelet Activating FactorThe serum concentration of Cimetidine can be decreased when it is combined with Platelet Activating Factor.Experimental
PodofiloxThe metabolism of Podofilox can be decreased when combined with Cimetidine.Approved
PomalidomideThe serum concentration of Pomalidomide can be decreased when it is combined with Cimetidine.Approved
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Cimetidine.Approved
PosaconazoleThe serum concentration of Posaconazole can be decreased when it is combined with Cimetidine.Approved, Investigational, Vet Approved
PramipexoleThe serum concentration of Pramipexole can be increased when it is combined with Cimetidine.Approved, Investigational
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Cimetidine.Approved
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Cimetidine.Approved
PraziquantelThe serum concentration of Praziquantel can be increased when it is combined with Cimetidine.Approved, Vet Approved
PrazosinThe serum concentration of Prazosin can be decreased when it is combined with Cimetidine.Approved
PrednisoloneThe serum concentration of Prednisolone can be decreased when it is combined with Cimetidine.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be decreased when it is combined with Cimetidine.Approved, Vet Approved
PregabalinThe serum concentration of Pregabalin can be increased when it is combined with Cimetidine.Approved, Illicit, Investigational
PrenylamineThe serum concentration of Prenylamine can be increased when it is combined with Cimetidine.Withdrawn
PrimidoneThe metabolism of Primidone can be decreased when combined with Cimetidine.Approved, Vet Approved
ProbenecidThe serum concentration of Cimetidine can be increased when it is combined with Probenecid.Approved
ProcainamideThe serum concentration of Procainamide can be increased when it is combined with Cimetidine.Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Cimetidine.Approved, Vet Approved
ProgesteroneThe serum concentration of Cimetidine can be decreased when it is combined with Progesterone.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Cimetidine.Approved
PromazineThe metabolism of Promazine can be decreased when combined with Cimetidine.Approved, Vet Approved
PromethazineThe serum concentration of Cimetidine can be increased when it is combined with Promethazine.Approved
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Cimetidine.Approved
PropofolThe metabolism of Propofol can be decreased when combined with Cimetidine.Approved, Investigational, Vet Approved
PropranololThe serum concentration of Propranolol can be decreased when it is combined with Cimetidine.Approved, Investigational
ProtriptylineThe metabolism of Protriptyline can be decreased when combined with Cimetidine.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Cimetidine.Approved
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Cimetidine.Approved
QuazepamThe metabolism of Quazepam can be decreased when combined with Cimetidine.Approved, Illicit
QuercetinThe serum concentration of Cimetidine can be increased when it is combined with Quercetin.Experimental
QuetiapineThe serum concentration of Quetiapine can be decreased when it is combined with Cimetidine.Approved
QuinacrineThe serum concentration of Cimetidine can be increased when it is combined with Quinacrine.Approved
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Cimetidine.Approved
QuinineThe serum concentration of Quinine can be increased when it is combined with Cimetidine.Approved
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Cimetidine.Approved, Investigational
RamelteonThe metabolism of Ramelteon can be decreased when combined with Cimetidine.Approved, Investigational
RanitidineThe serum concentration of Ranitidine can be decreased when it is combined with Cimetidine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Cimetidine.Approved, Investigational
ReboxetineThe serum concentration of Cimetidine can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Cimetidine can be increased when it is combined with Regorafenib.Approved
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Cimetidine.Approved, Withdrawn
repinotanThe metabolism of repinotan can be decreased when combined with Cimetidine.Investigational
ReserpineThe serum concentration of Cimetidine can be decreased when it is combined with Reserpine.Approved
RifampicinThe serum concentration of Cimetidine can be decreased when it is combined with Rifampicin.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Cimetidine.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Cimetidine.Approved
RisedronateThe serum concentration of Risedronate can be increased when it is combined with Cimetidine.Approved, Investigational
RisperidoneThe serum concentration of Risperidone can be decreased when it is combined with Cimetidine.Approved, Investigational
RitobegronRitobegron may decrease the sedative activities of Cimetidine.Investigational
RitonavirThe serum concentration of Cimetidine can be decreased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Cimetidine.Approved
RoflumilastThe serum concentration of the active metabolites of Roflumilast can be increased when Roflumilast is used in combination with Cimetidine.Approved
RolapitantThe serum concentration of Cimetidine can be increased when it is combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be decreased when it is combined with Cimetidine.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Cimetidine.Approved
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Cimetidine.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Cimetidine.Approved
Salicylic acidThe serum concentration of Salicylic acid can be decreased when it is combined with Cimetidine.Approved, Vet Approved
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Cimetidine.Approved, Investigational
ScopolamineThe serum concentration of Cimetidine can be increased when it is combined with Scopolamine.Approved
SelegilineThe serum concentration of Cimetidine can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be decreased when it is combined with Cimetidine.Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Cimetidine.Approved, Investigational
SertindoleThe metabolism of Sertindole can be decreased when combined with Cimetidine.Approved, Withdrawn
SertralineThe metabolism of Sertraline can be decreased when combined with Cimetidine.Approved
SildenafilThe metabolism of Sildenafil can be decreased when combined with Cimetidine.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Cimetidine.Approved
SimeprevirThe serum concentration of Simeprevir can be decreased when it is combined with Cimetidine.Approved
SimvastatinThe serum concentration of Cimetidine can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Cimetidine can be decreased when it is combined with Sirolimus.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be decreased when it is combined with Cimetidine.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Cimetidine.Approved
SorafenibThe serum concentration of Sorafenib can be decreased when it is combined with Cimetidine.Approved, Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Cimetidine.Approved
SparteineThe metabolism of Sparteine can be decreased when combined with Cimetidine.Experimental
SphingosineThe serum concentration of Sphingosine can be decreased when it is combined with Cimetidine.Experimental
SpironolactoneThe serum concentration of Cimetidine can be increased when it is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Cimetidine can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Cimetidine can be increased when it is combined with Staurosporine.Experimental
StreptozocinThe serum concentration of Cimetidine can be decreased when it is combined with Streptozocin.Approved
SulfinpyrazoneThe serum concentration of Cimetidine can be increased when it is combined with Sulfinpyrazone.Approved
SumatriptanThe serum concentration of Cimetidine can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Cimetidine can be increased when it is combined with Sunitinib.Approved, Investigational
TacrineThe serum concentration of Cimetidine can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe serum concentration of Tacrolimus can be decreased when it is combined with Cimetidine.Approved, Investigational
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Cimetidine resulting in a loss in efficacy.Approved
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Cimetidine.Approved, Investigational
TapentadolThe metabolism of Tapentadol can be decreased when combined with Cimetidine.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be decreased when it is combined with Cimetidine.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Cimetidine.Approved
TegafurThe serum concentration of the active metabolites of Tegafur can be increased when Tegafur is used in combination with Cimetidine.Approved
TegaserodThe metabolism of Tegaserod can be decreased when combined with Cimetidine.Investigational, Withdrawn
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Cimetidine.Approved
TelmisartanThe serum concentration of Cimetidine can be increased when it is combined with Telmisartan.Approved, Investigational
TemazepamThe metabolism of Temazepam can be decreased when combined with Cimetidine.Approved
TemsirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Cimetidine.Approved
TeniposideThe metabolism of Teniposide can be decreased when combined with Cimetidine.Approved
TerazosinThe serum concentration of Cimetidine can be increased when it is combined with Terazosin.Approved
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Cimetidine.Approved, Investigational, Vet Approved
TerfenadineThe serum concentration of Cimetidine can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideThe serum concentration of Cimetidine can be increased when it is combined with Teriflunomide.Approved
TesmilifeneThe serum concentration of Cimetidine can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Cimetidine can be increased when it is combined with Testosterone.Approved, Investigational
TetrabenazineThe metabolism of Tetrabenazine can be decreased when combined with Cimetidine.Approved
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Cimetidine.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Theophylline can be decreased when combined with Cimetidine.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Cimetidine.Approved
TianeptineThe metabolism of Tianeptine can be decreased when combined with Cimetidine.Approved
TicagrelorThe serum concentration of Ticagrelor can be decreased when it is combined with Cimetidine.Approved
TiclopidineThe metabolism of Ticlopidine can be decreased when combined with Cimetidine.Approved
TimololThe serum concentration of Timolol can be decreased when it is combined with Cimetidine.Approved
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Cimetidine.Approved
TipranavirThe metabolism of Tipranavir can be decreased when combined with Cimetidine.Approved, Investigational
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Cimetidine.Approved
TofacitinibThe metabolism of Tofacitinib can be decreased when combined with Cimetidine.Approved, Investigational
TolazamideThe serum concentration of Tolazamide can be increased when it is combined with Cimetidine.Approved
TolbutamideThe serum concentration of Tolbutamide can be increased when it is combined with Cimetidine.Approved
Tolfenamic AcidThe serum concentration of Tolfenamic Acid can be increased when it is combined with Cimetidine.Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Cimetidine.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Cimetidine.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Cimetidine.Approved, Investigational
ToremifeneThe serum concentration of Toremifene can be decreased when it is combined with Cimetidine.Approved, Investigational
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Cimetidine.Approved, Investigational
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Cimetidine.Approved, Investigational
TranilastThe serum concentration of Tranilast can be increased when it is combined with Cimetidine.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be decreased when it is combined with Cimetidine.Approved
TrazodoneThe serum concentration of Cimetidine can be decreased when it is combined with Trazodone.Approved, Investigational
TrifluoperazineThe serum concentration of Cimetidine can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Cimetidine can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Cimetidine.Approved
TrimethoprimThe serum concentration of Cimetidine can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Cimetidine.Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Cimetidine.Withdrawn
TroleandomycinThe serum concentration of Cimetidine can be increased when it is combined with Troleandomycin.Approved
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Cimetidine.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be decreased when it is combined with Cimetidine.Approved
Valproic AcidThe metabolism of Valproic Acid can be decreased when combined with Cimetidine.Approved, Investigational
VareniclineThe serum concentration of Varenicline can be increased when it is combined with Cimetidine.Approved, Investigational
VecuroniumThe serum concentration of Vecuronium can be decreased when it is combined with Cimetidine.Approved
VenetoclaxThe serum concentration of Venetoclax can be decreased when it is combined with Cimetidine.Approved
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Cimetidine.Approved
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Cimetidine.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Cimetidine.Approved
VinblastineThe serum concentration of Vinblastine can be decreased when it is combined with Cimetidine.Approved
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Cimetidine.Approved, Investigational
VinorelbineThe serum concentration of Cimetidine can be increased when it is combined with Vinorelbine.Approved, Investigational
VinpocetineThe serum concentration of Vinpocetine can be increased when it is combined with Cimetidine.Investigational
VismodegibThe serum concentration of Vismodegib can be decreased when it is combined with Cimetidine.Approved
VoriconazoleThe metabolism of Voriconazole can be decreased when combined with Cimetidine.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Cimetidine.Approved
WarfarinCimetidine may increase the anticoagulant activities of Warfarin.Approved
XylometazolineThe serum concentration of Xylometazoline can be increased when it is combined with Cimetidine.Approved
YohimbineThe metabolism of Yohimbine can be decreased when combined with Cimetidine.Approved, Vet Approved
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Cimetidine.Approved
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Cimetidine.Approved, Illicit, Investigational
ZiconotideThe serum concentration of Ziconotide can be increased when it is combined with Cimetidine.Approved
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Cimetidine.Approved
ZimelidineThe metabolism of Zimelidine can be decreased when combined with Cimetidine.Withdrawn
ZolmitriptanThe serum concentration of Zolmitriptan can be increased when it is combined with Cimetidine.Approved, Investigational
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Cimetidine.Approved
ZuclopenthixolThe metabolism of Zuclopenthixol can be decreased when combined with Cimetidine.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Best effect when taken with food.
  • Limit caffeine intake.
References
Synthesis Reference

Saburo Uchikuga, Tomoyasu Tashiro, Yasuko Osawa, “Process for preparing the H.sub.2 -receptor antagonist cimetidine.” U.S. Patent US4413129, issued March, 1972.

US4413129
General References
  1. Michnovicz JJ, Galbraith RA: Cimetidine inhibits catechol estrogen metabolism in women. Metabolism. 1991 Feb;40(2):170-4. [PubMed:1988774 ]
External Links
ATC CodesA02BA01A02BA51
AHFS Codes
  • 56:28.12
PDB EntriesNot Available
FDA labelDownload (420 KB)
MSDSDownload (73.4 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9855
Blood Brain Barrier-0.6782
Caco-2 permeable-0.6358
P-glycoprotein substrateSubstrate0.7887
P-glycoprotein inhibitor INon-inhibitor0.8781
P-glycoprotein inhibitor IINon-inhibitor0.8382
Renal organic cation transporterInhibitor0.7233
CYP450 2C9 substrateNon-substrate0.8048
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.5795
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorInhibitor0.5773
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9575
Ames testNon AMES toxic0.837
CarcinogenicityNon-carcinogens0.9579
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.7341 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7983
hERG inhibition (predictor II)Non-inhibitor0.8745
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Glaxosmithkline
  • Apotex inc
  • Contract pharmacal corp
  • Dava pharmaceuticals inc
  • Endo pharmaceuticals inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Lek pharmaceuticals d d
  • Mylan pharmaceuticals inc
  • L perrigo co
  • Perrigo co
  • Pliva inc
  • Roxane laboratories inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Hospira inc
  • Luitpold pharmaceuticals inc
  • Teva parenteral medicines inc
  • Actavis mid atlantic llc
  • Duramed pharmaceuticals inc sub barr laboratories inc
  • Hi tech pharmacal co inc
  • Novex pharma
  • Pharmaceutical assoc inc div beach products
  • Teva pharmaceuticals usa
  • Wockhardt eu operations (swiss) ag
Packagers
Dosage forms
FormRouteStrength
LiquidOral300 mg
TabletOral400 mg/1
Tablet, film coatedOral200 mg/1
Tablet, film coatedOral300 mg/1
Tablet, film coatedOral400 mg/1
Tablet, film coatedOral800 mg/1
TabletOral200 mg/1
SolutionOral300 mg/5mL
TabletOral100 mg
TabletOral300 mg
TabletOral400 mg
TabletOral600 mg
TabletOral800 mg
SolutionIntramuscular; Intravenous150 mg
TabletOral200 mg
LiquidIntravenous6 mg
LiquidIntramuscular; Intravenous150 mg
LiquidOral60 mg
Prices
Unit descriptionCostUnit
Cimetidine 800 mg tablet2.7USD tablet
Tagamet 400 mg tablet2.51USD tablet
Cimetidine 150 mg/ml vial1.67USD ml
Cimetidine powder1.48USD g
Cimetidine 400 mg tablet1.44USD tablet
Tagamet 300 mg tablet1.28USD tablet
Cimetidine 300 mg tablet0.93USD tablet
Cimetidine 200 mg tablet0.46USD tablet
Cimetidine HCl 300 mg/5ml Solution0.38USD ml
Tagamet hb 200 mg tablet0.37USD tablet
Apo-Cimetidine 800 mg Tablet0.27USD tablet
Mylan-Cimetidine 800 mg Tablet0.27USD tablet
Acid reducer 200 mg tablet0.21USD tablet
Apo-Cimetidine 600 mg Tablet0.18USD tablet
Mylan-Cimetidine 600 mg Tablet0.18USD tablet
Novo-Cimetine 600 mg Tablet0.18USD tablet
Nu-Cimet 600 mg Tablet0.18USD tablet
Apo-Cimetidine 400 mg Tablet0.14USD tablet
Mylan-Cimetidine 400 mg Tablet0.14USD tablet
Novo-Cimetine 400 mg Tablet0.14USD tablet
Nu-Cimet 400 mg Tablet0.14USD tablet
Apo-Cimetidine 200 mg Tablet0.09USD tablet
Apo-Cimetidine 300 mg Tablet0.09USD tablet
Mylan-Cimetidine 300 mg Tablet0.09USD tablet
Novo-Cimetine 300 mg Tablet0.09USD tablet
Nu-Cimet 300 mg Tablet0.09USD tablet
Heartburn relief 200 mg tablet0.08USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point142 °CPhysProp
water solubility9380 mg/L (at 25 °C)MCFARLAND,JW ET AL. (2001)
logP0.40HANSCH,C ET AL. (1995)
logS-1.35ADME Research, USCD
Caco2 permeability-5.89ADME Research, USCD
pKa6.8TOMLINSON,E & HAFKENSCHEID,TL (1986)
Predicted Properties
PropertyValueSource
Water Solubility0.816 mg/mLALOGPS
logP0.44ALOGPS
logP-0.11ChemAxon
logS-2.5ALOGPS
pKa (Strongest Acidic)13.38ChemAxon
pKa (Strongest Basic)6.91ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area88.89 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity70.32 m3·mol-1ChemAxon
Polarizability27.47 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (10 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-002b-9510000000-36ce01132725fd5bf5d8View in MoNA
1D NMR1H NMR SpectrumNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as imidazoles. These are compounds containing an imidazole ring, which is an aromatic five-member ring with two nitrogen atoms at positions 1 and 3, and three carbon atoms.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassAzoles
Sub ClassImidazoles
Direct ParentImidazoles
Alternative Parents
Substituents
  • Heteroaromatic compound
  • Imidazole
  • Guanidine
  • Azacycle
  • Dialkylthioether
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Sulfenyl compound
  • Carboximidamide
  • Thioether
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organonitrogen compound
  • Imine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
The H2 subclass of histamine receptors mediates gastric acid secretion. Also appears to regulate gastrointestinal motility and intestinal secretion. Possible role in regulating cell growth and differentiation. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase and, through a separate G protein-dependent mechanism, the phosphoinositide/protein kinase (PKC) si...
Gene Name:
HRH2
Uniprot ID:
P25021
Molecular Weight:
40097.65 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Hernandez-Munoz R, Montiel-Ruiz C, Vazquez-Martinez O: Gastric mucosal cell proliferation in ethanol-induced chronic mucosal injury is related to oxidative stress and lipid peroxidation in rats. Lab Invest. 2000 Aug;80(8):1161-9. [PubMed:10950107 ]
  3. Kuint J, Linder N, Reichman B: Hypoxemia associated with cimetidine therapy in a newborn infant. Am J Perinatol. 1996 Jul;13(5):301-3. [PubMed:8863950 ]
  4. Takahashi HK, Watanabe T, Yokoyama A, Iwagaki H, Yoshino T, Tanaka N, Nishibori M: Cimetidine induces interleukin-18 production through H2-agonist activity in monocytes. Mol Pharmacol. 2006 Aug;70(2):450-3. Epub 2006 May 24. [PubMed:16723495 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Grundemann D, Liebich G, Kiefer N, Koster S, Schomig E: Selective substrates for non-neuronal monoamine transporters. Mol Pharmacol. 1999 Jul;56(1):1-10. [PubMed:10385678 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Wang DS, Jonker JW, Kato Y, Kusuhara H, Schinkel AH, Sugiyama Y: Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther. 2002 Aug;302(2):510-5. [PubMed:12130709 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid 11-beta-monooxygenase activity
Specific Function:
Has steroid 11-beta-hydroxylase activity. In addition to this activity, the 18 or 19-hydroxylation of steroids and the aromatization of androstendione to estrone have also been ascribed to cytochrome P450 XIB.
Gene Name:
CYP11B1
Uniprot ID:
P15538
Molecular Weight:
57572.44 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Trimethylamine monooxygenase activity
Specific Function:
Involved in the oxidative metabolism of a variety of xenobiotics such as drugs and pesticides. It N-oxygenates primary aliphatic alkylamines as well as secondary and tertiary amines. Plays an important role in the metabolism of trimethylamine (TMA), via the production of TMA N-oxide (TMAO). Is also able to perform S-oxidation when acting on sulfide compounds (PubMed:9224773).
Gene Name:
FMO3
Uniprot ID:
P31513
Molecular Weight:
60032.975 Da
References
  1. Cashman JR: Human flavin-containing monooxygenase: substrate specificity and role in drug metabolism. Curr Drug Metab. 2000 Sep;1(2):181-91. [PubMed:11465082 ]
  2. Cashman JR, Park SB, Berkman CE, Cashman LE: Role of hepatic flavin-containing monooxygenase 3 in drug and chemical metabolism in adult humans. Chem Biol Interact. 1995 Apr 28;96(1):33-46. [PubMed:7720103 ]
  3. Hai X, Adams E, Hoogmartens J, Van Schepdael A: Enantioselective in-line and off-line CE methods for the kinetic study on cimetidine and its chiral metabolites with reference to flavin-containing monooxygenase genetic isoforms. Electrophoresis. 2009 Apr;30(7):1248-57. doi: 10.1002/elps.200800604. [PubMed:19283698 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Nadp binding
Specific Function:
This protein is involved in the oxidative metabolism of a variety of xenobiotics such as drugs and pesticides. Form I catalyzes the N-oxygenation of secondary and tertiary amines.
Gene Name:
FMO1
Uniprot ID:
Q01740
Molecular Weight:
60310.285 Da
References
  1. Hai X, Adams E, Hoogmartens J, Van Schepdael A: Enantioselective in-line and off-line CE methods for the kinetic study on cimetidine and its chiral metabolites with reference to flavin-containing monooxygenase genetic isoforms. Electrophoresis. 2009 Apr;30(7):1248-57. doi: 10.1002/elps.200800604. [PubMed:19283698 ]
  2. Cashman JR: Human flavin-containing monooxygenase: substrate specificity and role in drug metabolism. Curr Drug Metab. 2000 Sep;1(2):181-91. [PubMed:11465082 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Romiti N, Tramonti G, Chieli E: Influence of different chemicals on MDR-1 P-glycoprotein expression and activity in the HK-2 proximal tubular cell line. Toxicol Appl Pharmacol. 2002 Sep 1;183(2):83-91. [PubMed:12387747 ]
  2. Lentz KA, Polli JW, Wring SA, Humphreys JE, Polli JE: Influence of passive permeability on apparent P-glycoprotein kinetics. Pharm Res. 2000 Dec;17(12):1456-60. [PubMed:11303953 ]
  3. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. [PubMed:12699389 ]
  4. van der Sandt IC, Blom-Roosemalen MC, de Boer AG, Breimer DD: Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines. Eur J Pharm Sci. 2000 Sep;11(3):207-14. [PubMed:11042226 ]
  5. Ito T, Yano I, Tanaka K, Inui KI: Transport of quinolone antibacterial drugs by human P-glycoprotein expressed in a kidney epithelial cell line, LLC-PK1. J Pharmacol Exp Ther. 1997 Aug;282(2):955-60. [PubMed:9262363 ]
  6. Adachi Y, Suzuki H, Sugiyama Y: Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8. [PubMed:11785684 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Quaternary ammonium group transmembrane transporter activity
Specific Function:
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creatinine, amantadine, memantine, acriflavine, 4-[4-(dimethylamino)-styryl]-N-methylpyridinium ASP, amiloride, metformin, N-1-methylnicotinamide (NMN), tetraethylammonium (TEA), 1-methyl-4-phenylpyridiniu...
Gene Name:
SLC22A2
Uniprot ID:
O15244
Molecular Weight:
62579.99 Da
References
  1. Urakami Y, Akazawa M, Saito H, Okuda M, Inui K: cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney. J Am Soc Nephrol. 2002 Jul;13(7):1703-10. [PubMed:12089365 ]
  2. Motohashi H, Uwai Y, Hiramoto K, Okuda M, Inui K: Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A). Eur J Pharmacol. 2004 Oct 25;503(1-3):25-30. [PubMed:15496291 ]
  3. Kakehi M, Koyabu N, Nakamura T, Uchiumi T, Kuwano M, Ohtani H, Sawada Y: Functional characterization of mouse cation transporter mOCT2 compared with mOCT1. Biochem Biophys Res Commun. 2002 Aug 23;296(3):644-50. [PubMed:12176030 ]
  4. Urakami Y, Okuda M, Masuda S, Saito H, Inui KI: Functional characteristics and membrane localization of rat multispecific organic cation transporters, OCT1 and OCT2, mediating tubular secretion of cationic drugs. J Pharmacol Exp Ther. 1998 Nov;287(2):800-5. [PubMed:9808712 ]
  5. Okuda M, Urakami Y, Saito H, Inui K: Molecular mechanisms of organic cation transport in OCT2-expressing Xenopus oocytes. Biochim Biophys Acta. 1999 Mar 4;1417(2):224-31. [PubMed:10082798 ]
  6. Pan BF, Sweet DH, Pritchard JB, Chen R, Nelson JA: A transfected cell model for the renal toxin transporter, rOCT2. Toxicol Sci. 1999 Feb;47(2):181-6. [PubMed:10220855 ]
  7. Dudley AJ, Bleasby K, Brown CD: The organic cation transporter OCT2 mediates the uptake of beta-adrenoceptor antagonists across the apical membrane of renal LLC-PK(1) cell monolayers. Br J Pharmacol. 2000 Sep;131(1):71-9. [PubMed:10960071 ]
  8. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
  9. Grundemann D, Liebich G, Kiefer N, Koster S, Schomig E: Selective substrates for non-neuronal monoamine transporters. Mol Pharmacol. 1999 Jul;56(1):1-10. [PubMed:10385678 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Secondary active organic cation transmembrane transporter activity
Specific Function:
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnicotinamide (NMN), 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP), the endogenous compounds choline, guanidine, histamine, epinephrine, adrenaline, noradrenaline and dopamine, and the drugs quinine...
Gene Name:
SLC22A1
Uniprot ID:
O15245
Molecular Weight:
61153.345 Da
References
  1. Zhang L, Dresser MJ, Gray AT, Yost SC, Terashita S, Giacomini KM: Cloning and functional expression of a human liver organic cation transporter. Mol Pharmacol. 1997 Jun;51(6):913-21. [PubMed:9187257 ]
  2. Zhang L, Schaner ME, Giacomini KM: Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). J Pharmacol Exp Ther. 1998 Jul;286(1):354-61. [PubMed:9655880 ]
  3. Kakehi M, Koyabu N, Nakamura T, Uchiumi T, Kuwano M, Ohtani H, Sawada Y: Functional characterization of mouse cation transporter mOCT2 compared with mOCT1. Biochem Biophys Res Commun. 2002 Aug 23;296(3):644-50. [PubMed:12176030 ]
  4. Zhang L, Dresser MJ, Chun JK, Babbitt PC, Giacomini KM: Cloning and functional characterization of a rat renal organic cation transporter isoform (rOCT1A). J Biol Chem. 1997 Jun 27;272(26):16548-54. [PubMed:9195965 ]
  5. Urakami Y, Okuda M, Masuda S, Saito H, Inui KI: Functional characteristics and membrane localization of rat multispecific organic cation transporters, OCT1 and OCT2, mediating tubular secretion of cationic drugs. J Pharmacol Exp Ther. 1998 Nov;287(2):800-5. [PubMed:9808712 ]
  6. Okuda M, Urakami Y, Saito H, Inui K: Molecular mechanisms of organic cation transport in OCT2-expressing Xenopus oocytes. Biochim Biophys Acta. 1999 Mar 4;1417(2):224-31. [PubMed:10082798 ]
  7. Jonker JW, Wagenaar E, Mol CA, Buitelaar M, Koepsell H, Smit JW, Schinkel AH: Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1 [Slc22a1]) gene. Mol Cell Biol. 2001 Aug;21(16):5471-7. [PubMed:11463829 ]
  8. Grundemann D, Liebich G, Kiefer N, Koster S, Schomig E: Selective substrates for non-neuronal monoamine transporters. Mol Pharmacol. 1999 Jul;56(1):1-10. [PubMed:10385678 ]
  9. Wang DS, Jonker JW, Kato Y, Kusuhara H, Schinkel AH, Sugiyama Y: Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther. 2002 Aug;302(2):510-5. [PubMed:12130709 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Toxin transporter activity
Specific Function:
Mediates potential-dependent transport of a variety of organic cations. May play a significant role in the disposition of cationic neurotoxins and neurotransmitters in the brain.
Gene Name:
SLC22A3
Uniprot ID:
O75751
Molecular Weight:
61279.485 Da
References
  1. Grundemann D, Schechinger B, Rappold GA, Schomig E: Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter. Nat Neurosci. 1998 Sep;1(5):349-51. [PubMed:10196521 ]
  2. Wu X, Huang W, Ganapathy ME, Wang H, Kekuda R, Conway SJ, Leibach FH, Ganapathy V: Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney. Am J Physiol Renal Physiol. 2000 Sep;279(3):F449-58. [PubMed:10966924 ]
  3. Kekuda R, Prasad PD, Wu X, Wang H, Fei YJ, Leibach FH, Ganapathy V: Cloning and functional characterization of a potential-sensitive, polyspecific organic cation transporter (OCT3) most abundantly expressed in placenta. J Biol Chem. 1998 Jun 26;273(26):15971-9. [PubMed:9632645 ]
  4. Grundemann D, Liebich G, Kiefer N, Koster S, Schomig E: Selective substrates for non-neuronal monoamine transporters. Mol Pharmacol. 1999 Jul;56(1):1-10. [PubMed:10385678 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Symporter activity
Specific Function:
Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. Transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without the involvement of sodium. Also relative uptake activity ratio of carnitine to TEA is 11.3.
Gene Name:
SLC22A5
Uniprot ID:
O76082
Molecular Weight:
62751.08 Da
References
  1. Wu X, Prasad PD, Leibach FH, Ganapathy V: cDNA sequence, transport function, and genomic organization of human OCTN2, a new member of the organic cation transporter family. Biochem Biophys Res Commun. 1998 May 29;246(3):589-95. [PubMed:9618255 ]
  2. Ohashi R, Tamai I, Yabuuchi H, Nezu JI, Oku A, Sai Y, Shimane M, Tsuji A: Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther. 1999 Nov;291(2):778-84. [PubMed:10525100 ]
  3. Wu X, Huang W, Prasad PD, Seth P, Rajan DP, Leibach FH, Chen J, Conway SJ, Ganapathy V: Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter. J Pharmacol Exp Ther. 1999 Sep;290(3):1482-92. [PubMed:10454528 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Transporter activity
Specific Function:
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name:
ABCB11
Uniprot ID:
O95342
Molecular Weight:
146405.83 Da
References
  1. Wang EJ, Casciano CN, Clement RP, Johnson WW: Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites. Pharm Res. 2003 Apr;20(4):537-44. [PubMed:12739759 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Jung KY, Takeda M, Kim DK, Tojo A, Narikawa S, Yoo BS, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of ochratoxin A transport by human organic anion transporters. Life Sci. 2001 Sep 21;69(18):2123-35. [PubMed:11669456 ]
  2. Khamdang S, Takeda M, Shimoda M, Noshiro R, Narikawa S, Huang XL, Enomoto A, Piyachaturawat P, Endou H: Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine. J Pharmacol Sci. 2004 Feb;94(2):197-202. [PubMed:14978359 ]
  3. Nagata Y, Kusuhara H, Endou H, Sugiyama Y: Expression and functional characterization of rat organic anion transporter 3 (rOat3) in the choroid plexus. Mol Pharmacol. 2002 May;61(5):982-8. [PubMed:11961115 ]
  4. Burckhardt BC, Brai S, Wallis S, Krick W, Wolff NA, Burckhardt G: Transport of cimetidine by flounder and human renal organic anion transporter 1. Am J Physiol Renal Physiol. 2003 Mar;284(3):F503-9. Epub 2002 Nov 12. [PubMed:12429554 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenadine. Transports benzylpenicillin (PCG), estrone-3-sulfate (E1S), cimetidine (CMD), 2,4-dichloro-phenoxyacetate (2,4-D), p-amino-hippurate (PAH), acyclovir (ACV) and ochratoxin (OTA).
Gene Name:
SLC22A8
Uniprot ID:
Q8TCC7
Molecular Weight:
59855.585 Da
References
  1. Jung KY, Takeda M, Kim DK, Tojo A, Narikawa S, Yoo BS, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of ochratoxin A transport by human organic anion transporters. Life Sci. 2001 Sep 21;69(18):2123-35. [PubMed:11669456 ]
  2. Khamdang S, Takeda M, Shimoda M, Noshiro R, Narikawa S, Huang XL, Enomoto A, Piyachaturawat P, Endou H: Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine. J Pharmacol Sci. 2004 Feb;94(2):197-202. [PubMed:14978359 ]
  3. Motohashi H, Uwai Y, Hiramoto K, Okuda M, Inui K: Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A). Eur J Pharmacol. 2004 Oct 25;503(1-3):25-30. [PubMed:15496291 ]
  4. Ohtsuki S, Kikkawa T, Mori S, Hori S, Takanaga H, Otagiri M, Terasaki T: Mouse reduced in osteosclerosis transporter functions as an organic anion transporter 3 and is localized at abluminal membrane of blood-brain barrier. J Pharmacol Exp Ther. 2004 Jun;309(3):1273-81. Epub 2004 Feb 4. [PubMed:14762099 ]
  5. Kobayashi Y, Ohshiro N, Tsuchiya A, Kohyama N, Ohbayashi M, Yamamoto T: Renal transport of organic compounds mediated by mouse organic anion transporter 3 (mOat3): further substrate specificity of mOat3. Drug Metab Dispos. 2004 May;32(5):479-83. [PubMed:15100168 ]
  6. Nagata Y, Kusuhara H, Endou H, Sugiyama Y: Expression and functional characterization of rat organic anion transporter 3 (rOat3) in the choroid plexus. Mol Pharmacol. 2002 May;61(5):982-8. [PubMed:11961115 ]
  7. Mori S, Takanaga H, Ohtsuki S, Deguchi T, Kang YS, Hosoya K, Terasaki T: Rat organic anion transporter 3 (rOAT3) is responsible for brain-to-blood efflux of homovanillic acid at the abluminal membrane of brain capillary endothelial cells. J Cereb Blood Flow Metab. 2003 Apr;23(4):432-40. [PubMed:12679720 ]
  8. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, Endou H: Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86. [PubMed:11306713 ]
  9. Bakhiya A, Bahn A, Burckhardt G, Wolff N: Human organic anion transporter 3 (hOAT3) can operate as an exchanger and mediate secretory urate flux. Cell Physiol Biochem. 2003;13(5):249-56. [PubMed:14586168 ]
  10. Tahara H, Kusuhara H, Chida M, Fuse E, Sugiyama Y: Is the monkey an appropriate animal model to examine drug-drug interactions involving renal clearance? Effect of probenecid on the renal elimination of H2 receptor antagonists. J Pharmacol Exp Ther. 2006 Mar;316(3):1187-94. Epub 2005 Nov 16. [PubMed:16291876 ]
  11. Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Cha SH, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem. 1999 May 7;274(19):13675-80. [PubMed:10224140 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Monovalent cation:proton antiporter activity
Specific Function:
Solute transporter for tetraethylammonium (TEA), 1-methyl-4-phenylpyridinium (MPP), cimetidine, N-methylnicotinamide (NMN), metformin, creatinine, guanidine, procainamide, topotecan, estrone sulfate, acyclovir, ganciclovir and also the zwitterionic cephalosporin, cephalexin and cephradin. Seems to also play a role in the uptake of oxaliplatin (a new platinum anticancer agent). Able to transport...
Gene Name:
SLC47A1
Uniprot ID:
Q96FL8
Molecular Weight:
61921.585 Da
References
  1. Lai Y, Sampson KE, Balogh LM, Brayman TG, Cox SR, Adams WJ, Kumar V, Stevens JC: Preclinical and clinical evidence for the collaborative transport and renal secretion of an oxazolidinone antibiotic by organic anion transporter 3 (OAT3/SLC22A8) and multidrug and toxin extrusion protein 1 (MATE1/SLC47A1). J Pharmacol Exp Ther. 2010 Sep 1;334(3):936-44. doi: 10.1124/jpet.110.170753. Epub 2010 Jun 2. [PubMed:20519552 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Symporter activity
Specific Function:
Sodium-ion dependent, low affinity carnitine transporter. Probably transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without the involvement of sodium. Relative uptake activity ratio of carnitine to TEA is 1.78. A key substrate of this transporter seems to be ergothioneine (ET).
Gene Name:
SLC22A4
Uniprot ID:
Q9H015
Molecular Weight:
62154.48 Da
References
  1. Yabuuchi H, Tamai I, Nezu J, Sakamoto K, Oku A, Shimane M, Sai Y, Tsuji A: Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J Pharmacol Exp Ther. 1999 May;289(2):768-73. [PubMed:10215651 ]
  2. Wu X, George RL, Huang W, Wang H, Conway SJ, Leibach FH, Ganapathy V: Structural and functional characteristics and tissue distribution pattern of rat OCTN1, an organic cation transporter, cloned from placenta. Biochim Biophys Acta. 2000 Jun 1;1466(1-2):315-27. [PubMed:10825452 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
Gene Name:
SLC22A11
Uniprot ID:
Q9NSA0
Molecular Weight:
59970.945 Da
References
  1. Khamdang S, Takeda M, Shimoda M, Noshiro R, Narikawa S, Huang XL, Enomoto A, Piyachaturawat P, Endou H: Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine. J Pharmacol Sci. 2004 Feb;94(2):197-202. [PubMed:14978359 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulfate, allopurinol, 5-fluorouracil, paclitaxel, L-ascorbic acid, salicylate, ethotrexate, and alpha-ketoglutarate.
Gene Name:
SLC22A7
Uniprot ID:
Q9Y694
Molecular Weight:
60025.025 Da
References
  1. Kobayashi Y, Ohshiro N, Shibusawa A, Sasaki T, Tokuyama S, Sekine T, Endou H, Yamamoto T: Isolation, characterization and differential gene expression of multispecific organic anion transporter 2 in mice. Mol Pharmacol. 2002 Jul;62(1):7-14. [PubMed:12065749 ]
  2. Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Cha SH, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem. 1999 May 7;274(19):13675-80. [PubMed:10224140 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23